WO2018108101A1 - {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法 - Google Patents

{[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法 Download PDF

Info

Publication number
WO2018108101A1
WO2018108101A1 PCT/CN2017/115909 CN2017115909W WO2018108101A1 WO 2018108101 A1 WO2018108101 A1 WO 2018108101A1 CN 2017115909 W CN2017115909 W CN 2017115909W WO 2018108101 A1 WO2018108101 A1 WO 2018108101A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystalline form
solid
hydroxypyridine
chlorophenyl
carbonyl
Prior art date
Application number
PCT/CN2017/115909
Other languages
English (en)
French (fr)
Inventor
陈敏华
张炎锋
邹坡
王金秋
张晓宇
Original Assignee
苏州科睿思制药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州科睿思制药有限公司 filed Critical 苏州科睿思制药有限公司
Priority to US16/468,848 priority Critical patent/US10703724B2/en
Priority to EP17881314.3A priority patent/EP3549932B1/en
Priority to KR1020197020266A priority patent/KR20190093651A/ko
Priority to CA3046377A priority patent/CA3046377C/en
Priority to AU2017376517A priority patent/AU2017376517B2/en
Priority to EP20190094.1A priority patent/EP3763703A3/en
Priority to CN201780075695.1A priority patent/CN110088088B/zh
Priority to ES17881314T priority patent/ES2831863T3/es
Priority to MX2019006883A priority patent/MX2019006883A/es
Priority to JP2019531739A priority patent/JP2020500925A/ja
Publication of WO2018108101A1 publication Critical patent/WO2018108101A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the invention relates to the field of pharmaceutical crystal technology. Specifically, a novel crystal form involving ⁇ [5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino ⁇ acetic acid, a preparation method thereof and use thereof belong to the field of medicine.
  • Anemia can be chronic (eg, anemia secondary to chronic kidney disease, anemia secondary to chronic heart failure, aging anaemia, chronic diseases such as inflammatory bowel disease or rheumatoid arthritis anemia, spinal dysplasia) Syndrome, myelofibrosis, and other aplastic or dysplastic anemia), subacute (eg, chemotherapy-induced anemia, for example, for the treatment of cancer, hepatitis C or other chronic diseases, chemistry that reduces bone marrow production) Treatment), acute (eg, blood loss from injury or surgery), nutritionally related (eg, iron deficiency or vitamin B12 deficiency), or hemoglobinopathy (eg, sickle cell disease, thalassemia, etc.).
  • Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor is a novel drug for the treatment of anemia. These drugs work by stabilizing the HIF complex and stimulating endogenous erythropoietin.
  • Solid chemical drugs have different crystal forms, which can cause differences in solubility, stability, fluidity, etc., thereby affecting the safety and effectiveness of pharmaceutical products containing the compound (see K. Knapman, Modern Drug Discovery, 3, 53-54, 57, 2000.), resulting in differences in clinical efficacy.
  • new crystalline forms of pharmaceutically active ingredients including anhydrates, hydrates, solvates, etc.
  • New crystalline forms of certain pharmaceutically useful compounds can also help improve the performance of the drug. It expands the formulation of raw materials that can be used in the formulation, such as improved dissolution, improved shelf life, easier processing, and the like.
  • Form A, Form B and Form C of Vadadustat are disclosed in WO2015073779.
  • Form B may be converted to Form A in the slurry at high temperature; the inventors have found that Form C has poor preparation repeatability; and the text discloses that Form A is suitable for formulation preparation, but the disclosure is not disclosed.
  • Important properties such as stability of the crystal form, solubility in biological media, and the like. Therefore, there is still a need in the art to systematically develop different crystal forms of Vadadustat, and to find a new crystal form more suitable for drug development, and to promote the preparation of a better formulation of the active pharmaceutical ingredient.
  • the invention provides the crystalline form CS1, the crystalline form CS2 and the crystalline form CS8 of Vadadustat, and the crystal form of the invention is simple in preparation method, and has stability, wettability, solubility, mechanical stability, tablet stability, formulation stability and There are advantages in processing properties, etc., which provide a new and better choice for the preparation of pharmaceutical preparations containing Vadadustat, which is very important for drug development.
  • the main object of the present invention is to provide a novel crystalline form of Vadadustat, a process for its preparation and its use.
  • the present invention provides a crystal form CS1 of Vadadustat (hereinafter referred to as "crystal form CS1").
  • the crystal form CS1 is an anhydride.
  • the X-ray powder diffraction of the crystal form CS1 has characteristic peaks at diffraction angle 2 ⁇ values of 13.9° ⁇ 0.2°, 15.3° ⁇ 0.2°, 15.6° ⁇ 0.2°, and 26.8° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystal form CS1 has one or more of the diffraction angle 2 ⁇ values of 17.0° ⁇ 0.2°, 19.1° ⁇ 0.2°, 23.5° ⁇ 0.2°, and 25.6° ⁇ 0.2°. Characteristic peaks.
  • the X-ray powder diffraction of the crystal form CS1 has characteristic peaks at diffraction angle 2 ⁇ values of 17.0° ⁇ 0.2°, 19.1° ⁇ 0.2°, 23.5° ⁇ 0.2°, and 25.6° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystalline form CS1 has a diffraction angle 2 ⁇ values of 13.9 ° ⁇ 0.2 °, 15.3 ° ⁇ 0.2 °, 15.6 ° ⁇ 0.2, 17.0 ° ⁇ 0.2 °, 19.1 ° ⁇ There are characteristic peaks at 0.2°, 23.5° ⁇ 0.2°, 25.6° ⁇ 0.2°, and 26.8° ⁇ 0.2°.
  • the X-ray powder of Form CS1 The diffraction spectrum is shown in Figure 1.
  • the crystal form CS1 provided by the present invention has a mass loss of about 1.3% when heated to 168 ° C when subjected to thermogravimetric analysis, and its TGA is as shown in FIG. 2 . Shown.
  • the present invention also provides a process for the preparation of the crystalline form CS1 of Vadadustat, which is 1) or 2):
  • ether solvent is methyl tert-butyl ether
  • the stirring time is 1-48 h, and preferably, the stirring time is 24 h.
  • the crystalline form CS1 of the present invention has the following beneficial properties:
  • the saturated form prepared in SGF simulated artificial gastric juice
  • the crystalline form CS1 of the present invention is higher than the patent form WO2015073779 Form A at 1 hour, 4 hours and 24 hours.
  • Drugs with low solubility often require high doses to achieve therapeutic plasma concentrations after oral administration.
  • the increase in the solubility of the crystalline form CS1 enables us to reduce the dose of the drug while ensuring the efficacy of the drug, thereby reducing the side effects of the drug and improving the safety of the drug.
  • the increase in the solubility of the crystalline form CS1 reduces the difficulty in the development of the formulation process and is advantageous for industrial production.
  • the crystal form CS1 is placed at 25 ° C / 60% relative humidity, 40 ° C / 75% relative humidity, and can be stabilized for at least 1 month.
  • the better stability of the crystalline form CS1 can reduce the risk of drug dissolution rate and bio-profit change due to the change of crystal form, which is of great significance for ensuring the efficacy and safety of the drug and preventing the occurrence of adverse drug reactions.
  • the better stability of the crystal form CS1 makes it more controllable during the crystallization process, and it is not easy to appear mixed crystals, and it is not easy to be converted into other crystal forms during the preparation process and storage process, thereby ensuring consistent and controllable sample quality. And to ensure that the dissolution profile of the formulation product does not change as the storage time changes.
  • the present invention provides a crystalline form CS2 of Vadadustat (hereinafter referred to as "crystalline form CS2").
  • the crystal form CS2 is a hydrate.
  • the X-ray powder diffraction of the crystalline form CS2 is at a diffraction angle 2 ⁇
  • the X-ray powder diffraction of the crystalline form CS2 has a characteristic peak at one or two or three of the diffraction angles 2 ⁇ of 12.6° ⁇ 0.2°, 13.4° ⁇ 0.2°, and 22.0° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystalline form CS2 also has a characteristic peak at a diffraction angle 2 ⁇ of 12.6° ⁇ 0.2°, 13.4° ⁇ 0.2°, and 22.0° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystalline form CS2 has characteristic peaks at one or two or three of the diffraction angles 2 ⁇ of 10.9° ⁇ 0.2°, 16.1° ⁇ 0.2°, and 20.1° ⁇ 0.2°. .
  • the X-ray powder diffraction of the crystalline form CS2 also has a characteristic peak at a diffraction angle 2 ⁇ of 10.9° ⁇ 0.2°, 16.1° ⁇ 0.2°, and 20.1° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystalline form CS2 is 10.9° ⁇ 0.2°, 12.6° ⁇ 0.2°, 13.4° ⁇ 0.2°, 14.1° ⁇ 0.2°, 15.0° at the diffraction angle 2 ⁇ . There are characteristic peaks at ⁇ 0.2°, 16.1° ⁇ 0.2°, 18.3° ⁇ 0.2°, 20.1° ⁇ 0.2°, and 22.0° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of Form CS2 is as shown in FIG.
  • the crystal form CS2 provided by the present invention when subjected to differential scanning calorimetry, is heated to an endothermic peak near 85 ° C, and its DSC chart is as shown in FIG. 5 . Shown.
  • the crystalline form CS2 provided by the present invention has a mass loss of about 5.5% when heated to 111 ° C when subjected to thermogravimetric analysis, and its TGA is as shown in FIG. 6 Shown.
  • the present invention also provides a method for preparing crystalline form CS2 of Vadadustat, which comprises dissolving Vadadustat in a solvent of ketone, 1,4-dioxane or dimethyl sulfoxide to a solution. Slowly adding water or dropping the solution into water, stirring at room temperature for a period of time, filtering and drying to obtain a solid;
  • the ketone solvent is acetone
  • the stirring time is from 1 to 48 h, more preferably 24 h.
  • the crystalline form CS2 of the present invention has the following beneficial properties:
  • crystal form CS2 is more stable than patent WO2015073779 crystal form A; crystal form CS2 is allowed to stand at 25 ° C / 60% relative humidity, 40 ° C / 75% relative humidity, 60 ° C / 75% relative humidity, at least one month stable; crystal form CS2 before and after grinding, crystal form unchanged.
  • the better stability of the crystalline form CS2 can reduce the risk of drug dissolution rate and bio-profit change due to the change of crystal form, which is of great significance for ensuring the efficacy and safety of the drug and preventing the occurrence of adverse drug reactions;
  • Good stability makes it more controllable during the crystallization process, it is not easy to appear mixed crystal, and it is not easy to be converted into other crystal forms during the preparation process and storage process, so as to ensure the quality of the sample is consistent and controllable, and ensure the preparation
  • the dissolution curve of the product does not change with the change of storage time.
  • the crystalline form CS2 has good mechanical stability, so that the crystalline drug has low requirements on the crystallization equipment, and no special post-treatment conditions are required, in the preparation process. It is more stable and can significantly reduce the development cost of drugs, improve the quality of drugs, and has strong economic value.
  • the crystal form CS2 has low wettability, 40% relative humidity to 80% relative humidity range, and the weight gain is 0.11%.
  • the wettability of crystalline form CS2 is low, and its crystalline drug is not demanding on packaging and storage conditions, which is beneficial to long-term storage of drugs, which will greatly reduce the cost of material packaging and storage and quality control; the low moisture absorption of crystalline CS2 makes it crystallized.
  • the type of drug does not require special drying conditions in the preparation process, simplifies the preparation and post-treatment process of the drug, is easy for industrial production, and significantly reduces the research and development cost of the drug.
  • the tableting is stable. Before and after 3KN, 7KN, and 14KN pressure compression, the crystal form CS2 did not change. From the perspective of product quality, the crystalline CS2 tablet has good stability, which can effectively improve the hardness/friability of the tableting process, cracking and other problems, and reduce the requirements for the previous process (such as raw material crushing size control). Dry moisture control, particle size and particle size distribution control make the process easier, improve product appearance and improve product quality.
  • the crystalline CS2 tablet has good stability, can improve the tableting speed and improve production efficiency; it does not need to use some expensive special auxiliary materials to improve the pressure stability and reduce the cost of the auxiliary materials;
  • the process feasibility of the direct compression of the crystalline CS2 is greatly simplified, which greatly simplifies the formulation process and reduces the cost of research and development and production.
  • the crystalline CS2 tablet has good stability and can be further processed into tablets, and the tablet is smaller in volume than other dosage forms, and is more convenient to carry and take, and can improve patient compliance.
  • the crystalline form CS2 has good stability in the preparation, and the crystalline form of the drug does not require strict packaging and storage conditions, which is beneficial to the long-term storage of the medicine, and will greatly reduce the packaging and storage of the material. Quality control costs.
  • the physical and chemical stability of the crystal form during the preparation of the preparation is good, which is beneficial to the production, packaging, storage and transportation of the medicine, ensuring product quality and facilitating industrial production.
  • the present invention provides a crystalline form CS8 (hereinafter referred to as "crystalline form CS8") of Vadadustat, which is an anhydride.
  • the X-ray powder diffraction of the crystal form CS8 has characteristic peaks at diffraction angles 2 ⁇ of 21.2° ⁇ 0.2°, 22.6° ⁇ 0.2°, and 26.8° ⁇ 0.2°.
  • the X-ray powder diffraction of the crystalline form CS8 is in the diffraction angle 2 ⁇ of 13.5° ⁇ 0.2°, 13.9° ⁇ 0.2°, 15.8° ⁇ 0.2°, 21.9° ⁇ 0.2°, and 28.7° ⁇ 0.2°. There are also characteristic peaks in one or more places.
  • the X-ray powder diffraction of the crystalline form CS8 is also at a diffraction angle 2 ⁇ of 13.5° ⁇ 0.2°, 13.9° ⁇ 0.2°, 15.8° ⁇ 0.2°, 21.9° ⁇ 0.2°, 28.7° ⁇ 0.2°. Characteristic peaks.
  • the X-ray powder diffraction of the crystalline form CS8 is 13.5° ⁇ 0.2°, 13.9° ⁇ 0.2°, 15.8° ⁇ 0.2°, 21.2° ⁇ 0.2°, 21.9° at the diffraction angle 2 ⁇ . There are characteristic peaks at ⁇ 0.2°, 22.6° ⁇ 0.2°, 26.8° ⁇ 0.2°, and 28.7° ⁇ 0.2°.
  • the X-ray powder diffraction pattern of Form CS8 is shown in FIG.
  • the DSC pattern of Form CS8 is as shown in FIG.
  • the present invention also provides a method for preparing the crystalline form CS8, which comprises dissolving Vadadustat solid in a mixed solvent of a ketone and water at 40 to 56 ° C, and placing the obtained clear solution in 5 At ° C, stir for a while and filter dry to give a solid.
  • the temperature of dissolution is preferably 50 ° C;
  • the ketone solvent is acetone
  • the volume ratio of acetone to water is 1:3 to 2:1, more preferably 6:7;
  • the agitation time is from 8 to 48 h, more preferably 16 h.
  • the crystalline form CS8 of the present invention has the following beneficial properties:
  • the solubility is high, and the solubility of the crystalline form CS8 of the present invention is higher than that of the patent WO2015073779 crystal form A in a saturated solution prepared in SGF (simulated artificial gastric juice) or water.
  • Low water soluble drugs often require high doses to achieve therapeutic plasma concentrations after oral administration.
  • the increase in the solubility of the crystalline form CS8 enables us to reduce the dose of the drug while ensuring the efficacy of the drug, thereby reducing the side effects of the drug and improving the safety of the drug.
  • the increase in the solubility of the crystalline form CS8 reduces the difficulty in the development of the formulation process. Conducive to industrial production.
  • the crystal form CS8 is placed at 25 ° C / 60% relative humidity, 40 ° C / 75% relative humidity, 60 ° C / 75% relative humidity, at least for 20 days.
  • the better stability of the crystalline form CS8 can reduce the risk of drug dissolution rate and bio-profit change due to the change of crystal form, which is of great significance for ensuring the efficacy and safety of the drug and preventing the occurrence of adverse drug reactions;
  • the good stability makes it more controllable during the crystallization process, and it is not easy to appear mixed crystals, and it is not easy to be converted into other crystal forms during the preparation process and storage process, thereby ensuring consistent and controllable sample quality.
  • the wettability is low, the wettability of the crystalline form CS8 is 0.06% at 80% relative humidity, and the wettability is 0.08% at 90% relative humidity, which is none or almost no wettability.
  • the crystal form of CS8 has low wettability, and its crystalline drug does not require strict packaging and storage conditions, which is beneficial to long-term storage of drugs, which will greatly reduce material packaging and storage and quality control costs.
  • the low moisture absorption of crystal form CS8 makes it crystallized.
  • the type of drug does not require special drying conditions in the preparation process, simplifies the preparation and post-treatment process of the drug, is easy for industrial production, and significantly reduces the research and development cost of the drug.
  • the "room temperature” means 10 to 30 °C.
  • the "volatilization” is accomplished by conventional methods in the art, such as fast swinging, slow swinging, and the like.
  • the fast swing means that the compound is dissolved in a specific system, and after being filtered, the open mouth is rapidly volatilized at a specific temperature.
  • the slow swing means that the compound is dissolved in a specific system, and after filtration, a sealing film is applied to the mouth of the container, and a small hole is marked on the needle by the needle to slowly evaporate.
  • the “stirring” is carried out by a conventional method in the art, such as magnetic stirring or mechanical stirring, and the stirring speed is 50 to 1800 rpm, preferably 300 to 900 rpm.
  • the "drying” can be carried out at room temperature or higher unless otherwise specified. Drying temperatures range from room temperature to about 60 ° C, or to 40 ° C, or to 50 ° C. The drying time can be from 2 to 48 hours, or overnight. The "drying” is carried out in a fume hood, a forced air oven or a vacuum oven.
  • crystal or “crystal form” refers to the characterization by the X-ray diffraction pattern shown.
  • Those skilled in the art will appreciate that the physicochemical properties discussed herein can be characterized, with experimental error depending on the conditions of the instrument, the preparation of the sample, and the purity of the sample.
  • the X-ray diffraction pattern will generally vary with the conditions of the instrument. It is particularly important to note that the relative intensities of the X-ray diffraction patterns may also vary with experimental conditions, so the order of peak intensities cannot be the sole or decisive factor.
  • the peak angle experiment Errors are usually 5% or less, and errors in these angles should also be taken into account, usually with an error of ⁇ 0.2°.
  • the overall offset of the peak angle is caused, and a certain offset is usually allowed.
  • the novel crystalline form CS1, crystalline form CS2, and crystalline form CS8 of the present invention are pure, unitary, and substantially free of any other crystalline form.
  • substantially free when used to refer to a new crystalline form means that the crystalline form contains less than 20% by weight of other crystalline forms, especially less than 10% by weight of other crystalline forms, more Other crystal forms of 5% by weight, more preferably less than 1% by weight of other crystal forms.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically and/or prophylactically effective amount of one or more of the crystalline form CS1, crystalline form CS2, and crystalline form CS8 of the present invention, and at least one pharmaceutically acceptable Acceptable excipients.
  • the present invention provides the use of one or more of Vadadustat's crystalline form CS1, crystalline form CS2 and crystalline form CS8 for the preparation of an anemia pharmaceutical preparation.
  • the present invention provides the use of the crystalline form CS1, crystalline form CS2, and crystalline form CS8 of Vadadustat for the preparation of an anemia pharmaceutical preparation for treating chronic kidney disease.
  • Figure 1 is an X-ray powder diffraction pattern of a crystalline form CS1 obtained according to Example 1 of the present invention.
  • Example 2 is a TGA diagram of a crystalline form CS1 obtained according to Example 1 of the present invention.
  • Fig. 3 is a 1 H NMR chart of the crystal form CS1 obtained in Example 1 according to the present invention.
  • Example 4 is an X-ray powder diffraction pattern of a crystalline form CS2 obtained according to Example 4 of the present invention.
  • Figure 5 is a DSC chart of a crystalline form CS2 obtained according to Example 4 of the present invention.
  • Figure 6 is a TGA diagram of a crystalline form CS2 obtained in accordance with Example 4 of the present invention.
  • Figure 7 is a 1 H NMR chart of the crystalline form CS2 obtained in Example 4 according to the present invention.
  • Figure 8 is an X-ray powder diffraction pattern of a crystalline form CS8 obtained according to Example 8 of the present invention.
  • Figure 9 is a DSC chart of a crystalline form CS8 obtained in accordance with Example 8 of the present invention.
  • Fig. 10A shows the crystal form CS1 at 25 ° C / 60% relative humidity (top of the figure, the figure below is the crystal form after one month of standing).
  • Fig. 10B is a comparison chart of XRPDs placed at a temperature of 40 ° C / 75% relative humidity (the upper graph is the starting point, and the lower graph is the crystal form after one month of standing).
  • Fig. 11A shows the crystal form CS2 at 25 ° C / 60% relative humidity (the upper graph is the starting crystal form, and the lower graph is the crystal form after standing for 1 month).
  • Fig. 11B is 40 ° C / 75% relative humidity (the upper graph is the starting crystal form, and the lower graph is the crystal form after one month of standing).
  • Fig. 11C is a comparison chart of XRPDs placed at a temperature of 60 ° C / 75% relative humidity (the upper graph is the starting crystal form, and the lower graph is the crystal form after one month of standing) for one month.
  • Figure 12 is a comparison of the XRPD of the crystalline form CS2 before and after grinding (the upper picture shows the starting crystal form, and the lower figure shows the crystal form after grinding).
  • Figure 13 is a comparison of XRPD of the suspension competition process between the crystalline form CS2 and the patent WO2015073779 Form A.
  • Figure 14 is a DVS diagram of the crystal form CS8.
  • Figure 15 is an XRPD comparison chart of the stability of the crystalline CS2 tablet (the upper graph shows the XRPD before tableting, and the XRPD after tableting is the following three graphs, and the pressure from top to bottom is 3KN, 7KN, 14KN in order).
  • the X-ray powder diffraction pattern of the present invention was collected on a Bruker D2 PHASER X-ray powder diffractometer.
  • the method parameters of the X-ray powder diffraction described in the present invention are as follows:
  • Scan range: from 3.0 to 40.0 degrees
  • the differential scanning calorimetry (DSC) map of the present invention was acquired on a TA Q2000.
  • the method parameters of the differential scanning calorimetry (DSC) described in the present invention are as follows:
  • thermogravimetric analysis (TGA) map of the present invention was taken on a TA Q5000.
  • the method parameters of the thermogravimetric analysis (TGA) described in the present invention are as follows:
  • the dynamic moisture adsorption (DVS) pattern of the present invention was collected on an Intrinsic dynamic moisture adsorber manufactured by SMS Corporation (Surface Measurement Systems Ltd.).
  • the instrument control software is DVS-Intrinsic control software
  • the analysis software is DVS-Intrinsic Analysis software.
  • the method parameters of the dynamic moisture adsorber are as follows:
  • Relative humidity range 0%RH-95%RH
  • Nuclear magnetic resonance spectroscopy data ( 1 H NMR) were taken from a Bruker Avance II DMX 400M HZ NMR spectrometer. A sample of 1-5 mg was weighed and dissolved in 0.5 mL of deuterated dimethyl sulfoxide to prepare a solution of 2-10 mg/mL.
  • Vadadustat solid 11.3 mg was placed in a 1.5 mL glass vial, 0.5 mL of methyl tert-butyl ether was added, and the solid was dissolved to give a clear solution. Volatilization at room temperature for 2 days gave a solid.
  • the solid obtained in this example was a crystalline form CS1.
  • X-ray of solid obtained in this example The powder diffraction data is shown in Table 1, and its XRPD pattern is shown in Fig. 1.
  • the TGA of the crystal form CS1 is heated to 168 ° C as shown in Fig. 2, and has a weight loss of 1.3%.
  • Vadadustat solid 8.7 mg was placed in a 1.5 mL glass vial, 0.1 mL of tetrahydrofuran was added, and the solid was dissolved to give a clear solution. The clarified solution was slowly dropped into 1.5 mL of water under magnetic stirring. Stirring was continued for 24 h at room temperature and dried by filtration to give a solid.
  • the solid obtained in this example was a crystalline form CS1.
  • the X-ray powder diffraction data of the solid obtained in this example are shown in Table 2.
  • the crystalline form CS1 prepared by the present invention was allowed to stand under the conditions of 25 ° C / 60% relative humidity (RH) and 40 ° C / 75% relative humidity (RH) for 1 month, and the XRPD was measured before and after the separation. See Table 4, the XRPD comparison chart before and after placement is shown in Figure 10.
  • the results show that the crystalline form CS1 remains unchanged at 25 ° C / 60% RH, 40 ° C / 75% RH for 1 month.
  • the crystal form CS1 provided by the invention has good stability.
  • Vadadustat solid 118.5 mg was placed in a 3 mL glass vial, 1 mL of acetone was added, and the solid was dissolved to give a clear solution. The clear solution was slowly dropped into 15 mL of water under magnetic stirring. Stirring was continued for 24 h at room temperature and dried by filtration to give a solid.
  • the solid obtained in this example was a crystalline form CS2.
  • the X-ray powder diffraction data of the solid obtained in this example are shown in Table 5, and the XRPD pattern thereof is shown in Fig. 4.
  • the DSC image of the crystal form CS2 is shown in Fig. 5.
  • dehydration is started, and the crystal form CS2 is a hydrate.
  • the TGA of the crystal form CS2 is as shown in Fig. 6, and when heated to 111 ° C, there is a weight loss of 5.5%. According to the results of TGA, about 1 mole of water was contained per mole of the crystalline form CS2.
  • the 1 H NMR of the crystal form CS2 is shown in Fig. 7.
  • Vadadustat solid 8.5 mg was placed in a 1.5 mL glass vial, 0.075 mL of acetone was added, and the solid was dissolved to give a clear solution. With magnetic stirring, 1.5 mL of water was slowly dropped into the clear solution. Stirring was continued for 24 h at room temperature and dried by filtration to give a solid.
  • the solid obtained in this example was a crystalline form CS2.
  • the X-ray powder diffraction data of the solid obtained in this example are shown in Table 6.
  • Vadadustat solid 9.2 mg was placed in a 1.5 mL glass vial, 0.1 mL of 1,4-dioxane was added, and the solid was dissolved to give a clear solution. With magnetic stirring, 1.5 mL of water was slowly dropped into the clear solution. Stirring was continued for 24 h at room temperature and dried by filtration to give a solid.
  • the solid obtained in this example was a crystalline form CS2.
  • the X-ray powder diffraction data of the solid obtained in this example are shown in Table 7.
  • Vadadustat solid 8.2 mg was placed in a 1.5 mL glass vial, 0.05 mL of dimethyl sulfoxide was added, and the solid was dissolved to give a clear solution. With magnetic stirring, 1.5 mL of water was slowly dropped into the clear solution. Stirring was continued for 24 h at room temperature and dried by filtration to give a solid.
  • the solid obtained in this example was a crystalline form CS2.
  • the X-ray powder diffraction data of the solid obtained in this example are shown in Table 8.
  • Stability comparison experiment Weigh about 4 mg of crystalline form CS2 and about 4 mg of patent WO2015073779 crystal form A in a 1.5 mL glass vial, add 1.0 mL of water, test the crystal form of the starting sample, and stir at room temperature at a rate of 500 r/min. For about 40 days, the XRPD test was performed again, and the XRPD comparison chart is shown in FIG. The results show that when the suspension competition experiment is carried out for 40 days, the patent WO2015073779 crystal form A has been basically transformed into the crystal form CS2, indicating that the crystal form CS2 in water is more stable than the patent form WO2015073779 crystal form A.
  • the crystalline form CS2 prepared by the present invention is placed at 25 ° C / 60% relative humidity (RH), 40 ° C / 75% relative humidity (RH), 60 ° C / 75% relative humidity (RH). Months; XRPD before and after placement were measured, and the experimental results are shown in Table 9.
  • the XRPD comparison chart of the crystal form CS2 placed under the above conditions for 1 month is shown in Fig. 11. The results show that the crystalline form CS2 remains unchanged at 25 ° C / 60% RH, 40 ° C / 75% RH, 60 ° C / 75% RH for 1 month.
  • the crystal form CS2 was tableted using an ENERPAC type manual tableting machine. When pressing, select a circular punch with a diameter of 6mm (to ensure the isotropy of the tablet), and use a pressure of 3KN, 7KN, 14KN to make a round tablet, before and after the tableting in a Panalytical Empyrean X-ray powder diffractometer. Collect XRPD on it, as shown in Figure 15. The results showed that the crystal form did not change after tableting, and the crystal form CS2 had better tablet stability.
  • the crystal form CS2 and the auxiliary material were uniformly mixed, and the tablet was pressed by an ENERPAC type manual tableting machine.
  • a circular punch with a diameter of 6 mm was selected and the pressure was 10 KN, which was pressed into a round tablet.
  • the tablets were packaged in a HDPE bottle and placed under conditions of 30 ° C / 65% relative humidity for 3 months to examine the formulation stability of the crystalline form CS2. At the end of 3 months, samples were taken to detect changes in crystal form. The results showed that the crystalline form CS2 was stable for at least 3 months at 30 ° C / 65% relative humidity.
  • Vadadustat solid 8.3 mg was placed in a 1.5 mL glass vial, and 0.65 mL of a mixed solvent of acetone and water (volume ratio of acetone to water of 6:7) was added, and the solid was dissolved at 50 ° C to obtain a clear solution. The clear solution was transferred to a 5 ° C environment, stirred overnight, and a solid precipitated.
  • the solid obtained in this example was a crystalline form CS8.
  • the X-ray powder diffraction data of the solid obtained in this example is shown in Table 11, and its XRPD pattern is shown in Fig. 8.
  • the DSC chart of the crystal form CS8 is shown in Fig. 9.
  • the crystalline form CS8 prepared by the present invention is allowed to stand under the conditions of 5 ° C / 60% relative humidity (RH), 40 ° C / 75% relative humidity (RH), 60 ° C / 75% relative humidity (RH) for 20 days, respectively.
  • RH 60% relative humidity
  • RH 40 ° C / 75% relative humidity
  • RH 60 ° C / 75% relative humidity
  • the results show that the crystalline form CS8 remains unchanged at 25 ° C / 60% RH, 40 ° C / 75% RH, 60 ° C / 75% RH for 20 days.
  • the crystal form CS8 provided by the invention has good stability.
  • the Chinese Pharmacopoeia General Principles 9103 defines the wettability characteristics and the wettability weight gain:
  • Deliquescence absorbs enough water to form a liquid.
  • the wetting weight gain is not less than 15%.
  • the wetting weight gain is less than 15% but not less than 2%.
  • wetting gain is less than 0.2%.

Abstract

本发明涉及{[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法和用途。本发明制备得到的{[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的晶型CS1、晶型CS2、晶型CS8，可用于制备治疗贫血症药物制剂，为含{[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的药物制剂的制备提供了新的选择，对于药物开发具有非常重要的价值。

Description

{[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法 技术领域
本发明涉及药物晶体技术领域。具体而言，涉及{[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法和用途，属于医药领域。
背景技术
贫血可以是慢性的(例如，继发于慢性肾病的贫血、继发于慢性心力衰竭的贫血、衰老特发性贫血、慢性疾病例如炎症性肠病或类风湿性关节炎的贫血、脊髓发育不良综合征、骨髓纤维化、以及其他再生障碍性或发育不良性贫血)，亚急性的(例如，化学治疗诱导的贫血，例如，用于治疗癌症、丙肝或其他慢性疾病的，降低骨髓生产的化学治疗)，急性的(例如，来自损伤或手术的失血)，营养相关的(例如，缺铁或维生素B12缺乏)，或血红蛋白病(例如，镰刀形红细胞病、地中海贫血，等等)。低氧诱导因子(HIF)脯氨酰羟化酶抑制剂是一种新型的治疗贫血症的药物。这些药物通过稳定HIF复合物和刺激内源性***发挥作用。
{[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸，英文名称为Vadadustat，由Akebia公司研发，具有治疗或预防贫血的功能，作用机制为低氧诱导因子(HIF)脯氨酰羟化酶抑制剂，其作为治疗继发性慢性肾病引发的贫血症处于临床三期。其结构式如式(I)所示：
Figure PCTCN2017115909-appb-000001
固体化学药物晶型不同，可造成其溶解度、稳定性、流动性等不同，从而影响含有该化合物的药物产品的安全性和有效性(参见K.Knapman,Modern Drug Discovery,3,53-54,57,2000.)，从而导致临床药效的差异。发现药物活性成分新的晶型(包括无水物、水合物、溶剂化物等)可能会产 生更具加工优势或提供具有更好理化特性的物质，比如更好的生物利用度、储存稳定、易加工处理、易提纯或作为促进转化为其他晶型的中间体晶型。某些药学上有用的化合物的新晶型也可以帮助改善药物的性能。它扩大了制剂学上可选用的原料型态，例如改善溶出度、改善储藏期限、更容易加工等。
WO2015073779中公开了Vadadustat的晶型A、晶型B与晶型C。该专利文本中披露，晶型B高温下在浆液中可能转换为晶型A；经本发明人研究发现晶型C制备重复性差；同时该文本披露晶型A适用于制剂制备，但未披露该晶型的稳定性、在生物介质中的溶解度等重要性质。因此，本领域仍需要***全面的开发Vadadustat不同的晶型，需找更适合药物开发的的新晶型，促进该活性药物成分的更好的配方的制备。
本发明提供了Vadadustat的晶型CS1、晶型CS2和晶型CS8，本发明的晶型制备方法简单，其在稳定性、引湿性、溶解度、机械稳定性、压片稳定性、制剂稳定性以及加工性能等方面存在优势，为含Vadadustat的药物制剂的制备提供了新的更好的选择，对于药物开发具有非常重要的意义。
发明内容
本发明的主要目的是提供Vadadustat的新晶型及其制备方法和用途。
根据本发明的目的，本发明提供Vadadustat的晶型CS1(以下称作“晶型CS1”)。所述晶型CS1为无水物。
使用Cu-Kα辐射，所述晶型CS1的X射线粉末衍射在衍射角2θ值为13.9°±0.2°、15.3°±0.2°、15.6°±0.2°、26.8°±0.2°处有特征峰。
进一步的，所述晶型CS1的X射线粉末衍射在衍射角2θ值为17.0°±0.2°、19.1°±0.2°、23.5°±0.2°、25.6°±0.2°中的一处或多处有特征峰。
更进一步的，所述晶型CS1的X射线粉末衍射在衍射角2θ值为17.0°±0.2°、19.1°±0.2°、23.5°±0.2°、25.6°±0.2°处均有特征峰。
在一个优选的实施方案中，所述晶型CS1的X射线粉末衍射在衍射角2θ值为13.9°±0.2°、15.3°±0.2°、15.6°±0.2、17.0°±0.2°、19.1°±0.2°、23.5°±0.2°、25.6°±0.2°、26.8°±0.2°处有特征峰。
非限制性地，在本发明的一个具体实施方案中，晶型CS1的X射线粉末 衍射谱图如附图1所示。
非限制性地，在本发明的一个具体实施方案中，本发明提供的晶型CS1，当进行热重分析时，加热至168℃时，具有约1.3％的质量损失，其TGA如附图2所示。
非限制性地，在本发明的一个具体实施方案中，晶型CS1的1H NMR图如附图3所示。
根据本发明的目的，本发明还提供Vadadustat的晶型CS1的制备方法，所述方法为1)或2)：
1)将Vadadustat固体溶于醚类溶剂中，于室温下挥发得到固体；或
2)将Vadadustat固体溶于四氢呋喃溶剂中，向溶液中缓慢滴加水或者将溶液滴加到水中，于室温下搅拌一段时间，过滤干燥得到固体。
其中，所述醚类溶剂为甲基叔丁基醚；
所述搅拌时间为1-48h，优选的，搅拌时间为24h。
本发明的晶型CS1具有以下有益性质：
溶解度高。在SGF(模拟人工胃液)中配制成的饱和溶液，本发明的晶型CS1在1小时、4小时和24小时时，均比专利WO2015073779晶型A高。溶解度低的药物常常需要高剂量才能在口服后达到治疗血浆浓度。晶型CS1溶解度的升高能够使我们在保证药物疗效的同时，降低药品的剂量，从而降低药品的副作用并提高药品的安全性。同时，晶型CS1溶解度的提高降低了制剂工艺开发的难度，有利于工业生产。
稳定性好。晶型CS1在25℃/60％相对湿度、40℃/75％相对湿度下放置，至少可以稳定1个月。晶型CS1较好的稳定性能够减少药物由于晶型变化而导致药物溶出速率及生物利度改变的风险，对保证药物疗效和安全性，防止药物不良反应的发生具有重要意义。晶型CS1较好的稳定性使其在结晶工艺过程中更加可控，不容易出现混晶，且在制剂工艺及储存过程中，不容易转变成其它晶型，从而保证样品的质量一致可控，并确保制剂产品的溶出曲线不会随着储存的时间变化而发生改变。
根据本发明的目的，本发明提供Vadadustat的晶型CS2(以下称作“晶型CS2”)。所述晶型CS2为水合物。
使用Cu-Kα辐射，所述晶型CS2的X-射线粉末衍射在衍射角2θ为 14.1°±0.2°、15.0°±0.2°、18.3°±0.2°处有特征峰。
进一步的，所述晶型CS2的X-射线粉末衍射在衍射角2θ为12.6°±0.2°、13.4°±0.2°、22.0°±0.2°中的一处或两处或三处具有特征峰。
优选的，所述晶型CS2的X-射线粉末衍射在衍射角2θ为12.6°±0.2°、13.4°±0.2°、22.0°±0.2°处也有特征峰。
更进一步的，所述晶型CS2的X-射线粉末衍射在衍射角2θ为10.9°±0.2°、16.1°±0.2°、20.1°±0.2°中的一处或两处或三处具有特征峰。
优选的，所述晶型CS2的X-射线粉末衍射在衍射角2θ为10.9°±0.2°、16.1°±0.2°、20.1°±0.2°处也有特征峰。
在一个优选的实施方案中，所述晶型CS2的X-射线粉末衍射在衍射角2θ为10.9°±0.2°、12.6°±0.2°、13.4°±0.2°、14.1°±0.2°、15.0°±0.2°、16.1°±0.2°、18.3°±0.2°、20.1°±0.2°、22.0°±0.2°处有特征峰。
非限制性地，在本发明的一个具体实施方案中，晶型CS2的X射线粉末衍射谱图如附图4所示。
非限制性地，在本发明的一个具体实施方案中，本发明提供的晶型CS2，当进行差示扫描量热分析时，加热至85℃附近出现吸热峰，其DSC图如附图5所示。
非限制性地，在本发明的一个具体实施方案中，本发明提供的晶型CS2，当进行热重分析时，加热至111℃时，具有约5.5％的质量损失，其TGA如附图6所示。
非限制性地，在本发明的一个具体实施方案中，晶型CS2的1H NMR图如附图7所示。
根据本发明的目的，本发明还提供Vadadustat的晶型CS2的制备方法，所述方法为：将Vadadustat溶解到酮类、1,4-二氧六环，二甲亚砜溶剂中，向溶液中缓慢添加水或者将溶液滴加到水中，于室温下搅拌一段时间，过滤干燥得到固体；
优选的，所述酮类溶剂为丙酮；
优选的，所述搅拌时间为1-48h，更优选为24h。
本发明的晶型CS2具有以下有益性质：
稳定性好。在水中，晶型CS2比专利WO2015073779晶型A更稳定；晶型 CS2在25℃/60％相对湿度、40℃/75％相对湿度、为60℃/75％相对湿度下放置，至少可以稳定1个月；晶型CS2在研磨前后，晶型无变化。晶型CS2较好的稳定性能够减少药物由于晶型变化而导致药物溶出速率及生物利度改变的风险，对保证药物疗效和安全性，防止药物不良反应的发生具有重要意义；晶型CS2较好的稳定性使其在结晶工艺过程中更加可控，不容易出现混晶，且在制剂工艺及储存过程中，不容易转变成其它晶型，从而保证样品的质量一致可控，并确保制剂产品的溶出曲线不会随着储存的时间变化而发生改变；同时，晶型CS2具有较好的机械稳定性使其晶型药物对结晶设备要求低，无需特别的后处理条件，在制剂过程中更加稳定，可显著降低药物的开发成本，提升药物质量，具有很强的经济价值。
引湿性低。晶型CS2引湿性低，40％相对湿度到80％相对湿度区间，增重0.11％。晶型CS2的引湿性低，其晶型药物对包装和贮存条件要求不苛刻，有利于药品的长期贮存，将大大降低物料包装和贮存以及质量控制成本；晶型CS2的低引湿性使其晶型药物在制备过程中无需特殊的干燥条件，简化了药物的制备与后处理工艺，易于工业化生产，显著降低了药物的研发成本。
压片稳定性好。3KN、7KN、14KN压力压片前后，晶型CS2没有发生变化。从产品质量的角度看，晶型CS2压片稳定性好，可以有效改善压片过程中的硬度/脆碎度不合格、裂片等问题，降低对前续工艺处理的要求(如原料粉碎粒度控制、干燥水分控制、颗粒的粒径及粒径分布控制)，使工艺更为简便，改善产品外观，提升产品质量。从生产效率及成本的角度看，晶型CS2压片稳定性好，可提升压片速度，提高生产效率；工艺过程中无需使用一些昂贵的特殊辅料改善压力稳定性，减少了辅料的成本支出；另外，晶型CS2直接压片的工艺可行性提高，大大简化了制剂工艺过程，降低了研发和生产的成本。从患者顺应性的角度看，晶型CS2压片稳定性好，可进一步加工成片剂，而片剂相对其它剂型体积更小，携带和服用更为方便，可提高患者的顺应性。
制剂中稳定性好。晶型CS2制成片剂后在30℃/65％相对湿度条件下至少可以稳定3个月。晶型CS2在制剂中稳定性好，其晶型药物对包装和贮存条件要求不苛刻，有利于药品的长期贮存，将大大降低物料包装和贮存以及 质量控制成本。制剂制备过程中晶型的物理及化学稳定性良好，有利于药品的生产、包装、储存及运输，保证产品质量，便于工业化生产。
根据本发明的目的，本发明提供Vadadustat的晶型CS8(以下称作“晶型CS8”)，所述晶型CS8为无水物。
使用Cu-Kα辐射，所述晶型CS8的X-射线粉末衍射在衍射角2θ为21.2°±0.2°、22.6°±0.2°、26.8°±0.2°处有特征峰。
进一步的，所述晶型CS8的X-射线粉末衍射在衍射角2θ为13.5°±0.2°、13.9°±0.2°、15.8°±0.2°、21.9°±0.2°、28.7°±0.2°中的一处或多处也有特征峰。
优选的，所述晶型CS8的X-射线粉末衍射在衍射角2θ为13.5°±0.2°、13.9°±0.2°、15.8°±0.2°、21.9°±0.2°、28.7°±0.2°处也有特征峰。
在一个优选的实施方案中，所述晶型CS8的X-射线粉末衍射在衍射角2θ为13.5°±0.2°、13.9°±0.2°、15.8°±0.2°、21.2°±0.2°、21.9°±0.2°、22.6°±0.2°、26.8°±0.2°、28.7°±0.2°处有特征峰。
非限制性地，在本发明的一个具体实施方案中，晶型CS8的X-射线粉末衍射谱图如图8所示。
非限制性地，在本发明的一个具体实施方案中，晶型CS8的DSC图如附图9所示。
根据本发明的目的，本发明还提供所述晶型CS8的制备方法，所述制备方法包括:将Vadadustat固体溶解于40～56℃酮类和水的混合溶剂中，将所得澄清溶液置于5℃，搅拌一段时间，过滤干燥得到固体。
优选地，所述溶解的温度优选为50℃；
优选地，所述酮类溶剂为丙酮；
优选地，所述丙酮与水的体积比为1:3～2:1，更优选为6:7；
优选地，所述搅拌时间为8～48h，更优选为16h。
本发明的晶型CS8具有以下有益性质：
溶解度高，在SGF(模拟人工胃液)、水中配制成的饱和溶液，本发明晶型CS8的溶解度均比专利WO2015073779晶型A高。低水溶性药物常常需要高剂量才能在口服后达到治疗血浆浓度。晶型CS8溶解度的升高能够使我们在保证药物疗效的同时，降低药品的剂量，从而降低药品的副作用并提高药品的安全性。同时，晶型CS8溶解度的提高降低了制剂工艺开发的难度， 有利于工业生产。
稳定性好，晶型CS8在25℃/60％相对湿度、40℃/75％相对湿度、为60℃/75％相对湿度下放置，至少可以稳定20天。晶型CS8较好的稳定性能够减少药物由于晶型变化而导致药物溶出速率及生物利度改变的风险，对保证药物疗效和安全性，防止药物不良反应的发生具有重要意义；晶型CS8较好的稳定性使其在结晶工艺过程中更加可控，不容易出现混晶，且在制剂工艺及储存过程中，不容易转变成其它晶型，从而保证样品的质量一致可控。
引湿性低，晶型CS8在80％相对湿度引湿性为0.06％，90％相对湿度时引湿性为0.08％，属于无或几乎无引湿性。晶型CS8的引湿性低，其晶型药物对包装和贮存条件要求不苛刻，有利于药品的长期贮存，将大大降低物料包装和贮存以及质量控制成本；晶型CS8的低引湿性使其晶型药物在制备过程中无需特殊的干燥条件，简化了药物的制备与后处理工艺，易于工业化生产，显著降低了药物的研发成本。
在本发明的晶型CS1、CS2、CS8的制备方法中：
所述“室温”指10～30℃。
所述“挥发”，采用本领域的常规方法完成，例如快挥、慢挥等。所述快挥，是指将化合物溶于特定体系，经过滤后敞口置于特定温度下快速挥发。所述慢挥，是指将化合物溶于特定体系，经过滤后在容器口覆上一层封口膜，采用针头在其上戳几个小孔，缓慢挥发。
所述“搅拌”，采用本领域的常规方法完成，例如磁力搅拌或机械搅拌，搅拌速度为50～1800转/分钟，优选300～900转/分钟。
除非特别说明，所述“干燥”可以在室温或更高的温度下进行。干燥温度室温～约60℃，或者到40℃，或者到50℃。干燥时间可以为2～48小时，或者过夜。所述“干燥”在通风橱、鼓风烘箱或真空烘箱里进行。
本发明中，“晶体”或“晶型”指的是被所示的X射线衍射图表征所证实的。本领域技术人员能够理解，这里所讨论的理化性质可以被表征，其中的实验误差取决于仪器的条件、样品的准备和样品的纯度。特别是，本领域技术人员公知，X射线衍射图通常会随着仪器的条件而有所改变。特别需要指出的是，X射线衍射图的相对强度也可能随着实验条件的变化而变化，所以峰强度的顺序不能作为唯一或决定性因素。另外，峰角度的实验 误差通常在5％或更少，这些角度的误差也应该被考虑进去，通常允许有±0.2°的误差。另外，由于样品高度等实验因素的影响，会造成峰角度的整体偏移，通常允许一定的偏移。因而，本领域技术人员可以理解的是，本发明中一个晶型的X射线衍射图不必和这里所指的例子中的X射线衍射图完全一致。任何具有和这些图谱中的特征峰相同或相似的图的晶型均属于本发明的范畴之内。本领域技术人员能够将本发明所列的图谱和一个未知晶型的图谱相比较，以证实这两组图谱反映的是相同还是不同的晶型。
在一些实施方案中，本发明的新晶型CS1、晶型CS2和晶型CS8是纯的、单一的，基本没有混合任何其他晶型。本发明中，“基本没有”当用来指新晶型时指这个晶型含有少于20％(重量)的其他晶型，尤其指少于10％(重量)的其他晶型，更指少于5％(重量)的其他晶型，更指少于1％(重量)的其他晶型。
需要说明的是，本发明中提及的数值及数值范围不应被狭隘地理解为数值或数值范围本身，本领域技术人员应当理解其可以根据具体技术环境的不同，在不背离本发明精神和原则的基础上围绕具体数值有所浮动，本发明中，这种本领域技术人员可预见的浮动范围多以术语“约”来表示。
此外，本发明提供一种药物组合物，所述药物组合物包含治疗和/或预防有效量的本发明晶型CS1、晶型CS2、晶型CS8的一种或多种，以及至少一种药学上可接受的赋形剂。
进一步的，本发明提供Vadadustat的晶型CS1、晶型CS2和晶型CS8一种或多种在制备贫血病药物制剂中的用途。
更进一步的，本发明提供Vadadustat的晶型CS1、晶型CS2、晶型CS8在制备治疗慢性肾病引起的贫血药物制剂中的用途。
附图说明
图1为根据本发明实施例1所得晶型CS1的X射线粉末衍射图。
图2为根据本发明实施例1所得晶型CS1的TGA图。
图3为根据本发明实施例1所得晶型CS1的1H NMR图。
图4为根据本发明实施例4所得晶型CS2的X射线粉末衍射图。
图5为根据本发明实施例4所得晶型CS2的DSC图。
图6为根据本发明实施例4所得晶型CS2的TGA图。
图7为根据本发明实施例4所得晶型CS2的1H NMR图。
图8为根据本发明实施例8所得晶型CS8的X射线粉末衍射图。
图9为根据本发明实施例8所得晶型CS8的DSC图。
图10A为晶型CS1在25℃/60％相对湿度(上图为起始，下图为放置1个月后的晶型)。
图10B为40℃/75％相对湿度(上图为起始，下图为放置1个月后的晶型)的条件下放置1个月前后的XRPD对比图。
图11A为晶型CS2在25℃/60％相对湿度(上图为起始晶型，下图为放置1个月后的晶型)。
图11B为40℃/75％相对湿度(上图为起始晶型，下图为放置1个月后的晶型)。
图11C为60℃/75％相对湿度(上图为起始晶型，下图为放置1个月后的晶型)的条件下放置1个月前后的XRPD对比图。
图12研磨前后晶型CS2的XRPD对比图(上图为起始晶型，下图为研磨后的晶型)。
图13为晶型CS2与专利WO2015073779晶型A的混悬竞争过程的XRPD对比图。
图14为晶型CS8的DVS图。
图15为晶型CS2压片稳定性的XRPD对比图(上图为压片前的XRPD，压片后的XRPD为下面三个图，从上到下的压力依次为3KN、7KN、14KN)。
具体实施方式
本发明进一步参考以下实施例限定，所述实施例详细描述本发明的晶型的制备和使用方法。对本领域技术人员显而易见的是，对于材料和方法两者的许多改变可在不脱离本发明范围的情况下实施。
采集数据所用的仪器及方法：
本发明所述的X射线粉末衍射图在Bruker D2PHASER X射线粉末衍射仪上采集。本发明所述的X射线粉末衍射的方法参数如下：
X射线光源：Cu,Kα
Kα1
Figure PCTCN2017115909-appb-000002
1.54060；Kα2
Figure PCTCN2017115909-appb-000003
1.54439
Kα2/Kα1强度比例：0.50
电压：30仟伏特(kV)
电流：10毫安培(mA)
扫描范围：自3.0至40.0度
本发明所述的差示扫描量热分析(DSC)图在TA Q2000上采集。本发明所述的差示扫描量热分析(DSC)的方法参数如下：
扫描速率：10℃/min
保护气体：氮气
本发明所述的热重分析(TGA)图在TA Q5000上采集。本发明所述的热重分析(TGA)的方法参数如下：
扫描速率：10℃/min
保护气体：氮气
本发明所述动态水分吸附(DVS)图在由SMS公司(Surface Measurement Systems Ltd.)生产的Intrinsic动态水分吸附仪上采集。仪器控制软件是DVS-Intrinsic control software，分析软件是DVS-Intrinsic Analysis software。所述的动态水分吸附仪的方法参数如下：
温度：25℃
载气，流速：N2,200毫升/分钟
单位时间质量变化：0.002％/分钟
相对湿度范围：0％RH-95％RH
核磁共振氢谱数据(1H NMR)采自于Bruker Avance II DMX 400M HZ核磁共振波谱仪。称量1-5mg样品，用0.5mL氘代二甲亚砜溶解，配成2-10mg/mL的溶液。
除非特殊说明，以下实施例均在室温条件下操作。
实施例1 晶型CS1的制备方法
将11.3mg的Vadadustat固体置于1.5mL的玻璃小瓶中，加入0.5mL的甲基叔丁基醚，固体溶解得到澄清溶液。在室温下挥发2天得到固体。
经检测，本实施例得到的固体为晶型CS1。本实施例所得固体的X射线 粉末衍射数据如表1所示，其XRPD图如图1所示。
晶型CS1的TGA如图2所示，加热至168℃，有1.3％的失重。
晶型CS1的1H NMR如图3所示，核磁数据：1H NMR(400MHz,DMSO)δ12.82(s,1H),12.38(s,1H),9.38(t,J＝6.1Hz,1H),8.55(d,J＝1.9Hz,1H),7.93(s,1H),7.85-7.74(m,2H),7.60-7.49(m,2H),4.01(d,J＝6.2Hz,2H)。
表1
衍射角2θ d值 强度％
11.79 7.51 3.37
13.95 6.35 10.11
15.26 5.81 4.02
15.62 5.67 5.28
17.00 5.22 6.99
19.10 4.65 3.51
21.72 4.09 5.21
21.95 4.05 7.03
23.55 3.78 7.32
24.37 3.65 3.87
25.56 3.49 4.43
26.82 3.32 100.00
27.91 3.20 3.99
28.78 3.10 3.29
实施例2 晶型CS1的制备方法
将8.7mg的Vadadustat固体置于1.5mL的玻璃小瓶中，加入0.1mL的四氢呋喃，固体溶解得到澄清溶液。磁力搅拌下，将澄清溶液缓慢滴入1.5mL的水中。室温下继续搅拌24h，过滤干燥得到固体。
经检测，本实施例得到的固体为晶型CS1。本实施例所得固体的X射线粉末衍射数据如表2所示。
表2
衍射角2θ d值 相对强度％
11.83 7.48 4.31
13.94 6.35 5.12
15.27 5.80 2.57
15.66 5.66 2.94
17.07 5.20 3.35
18.64 4.76 2.37
19.13 4.64 2.98
21.78 4.08 5.85
23.57 3.77 7.28
25.54 3.49 3.45
26.83 3.32 100.00
28.77 3.10 2.29
35.15 2.55 0.72
实施例3 晶型CS1的溶解度
分别称取一定量的本发明晶型CS1和专利WO2015073779晶型A置于小瓶中，用SGF(模拟胃液)进行溶解。在旋转器上以25r/min的速率旋转，并分别于1小时、4小时和24小时取样，在使用0.45μm PTFE过滤器离心分离后，收集滤液进行HPLC分析，结果如表3所示。
表3
Figure PCTCN2017115909-appb-000004
结果表明，在SGF中放置1小时，4小时和24个小时后，本发明的晶型CS1与专利WO2015073779晶型A相比，其溶解度均高于专利WO2015073779晶型A的溶解度。
实施例4 晶型CS1的稳定性
将本发明制备得到的晶型CS1在25℃/60％相对湿度(RH)、40℃/75％相对湿度(RH)的条件下放置1个月，分别测定放置前后其XRPD，实验结果 见表4，放置前后的XRPD对比图如图10所示。
表4
Figure PCTCN2017115909-appb-000005
结果表明，晶型CS1在25℃/60％RH，40℃/75％RH条件下放置1个月晶型保持不变。本发明所提供晶型CS1具有良好的稳定性。
实施例5 晶型CS2的制备方法
将118.5mg的Vadadustat固体置于3mL的玻璃瓶中，加入1mL的丙酮，固体溶解得到澄清溶液。磁力搅拌下，将澄清溶液缓慢滴入15mL的水中。室温下继续搅拌24h，过滤干燥得到固体。
经检测，本实施例得到的固体为晶型CS2。本实施例所得固体的X射线粉末衍射数据如表5所示，其XRPD图如图4所示。
晶型CS2的DSC图像如图5所示，当加热至85℃，开始脱水，晶型CS2为水合物。
晶型CS2的TGA如图6所示，加热至111℃时，有5.5％的失重。按照TGA的结果计算，每摩尔的晶型CS2中含有约1摩尔的水。
晶型CS2的1H NMR如图7所示，核磁数据：1H NMR(400MHz,DMSO)δ12.84(s,1H),12.39(s,1H),9.39(t,J＝6.1Hz,1H),8.56(d,J＝1.9Hz,1H),7.94(s,1H),7.85-7.75(m,2H),7.60-7.49(m,2H),4.01(d,J＝6.2Hz,2H).
表5
衍射角2θ d值 相对强度％
3.63 24.32 8.43
10.95 8.08 66.50
12.60 7.03 19.75
13.38 6.62 67.46
14.10 6.28 28.25
14.59 6.07 7.96
15.04 5.89 82.04
16.10 5.50 36.21
17.34 5.11 10.89
18.31 4.84 100.00
20.05 4.43 35.62
21.45 4.14 15.25
21.99 4.04 71.74
24.44 3.64 56.69
25.43 3.50 49.03
25.77 3.46 45.28
26.97 3.31 18.18
27.92 3.20 8.99
28.48 3.13 16.19
29.13 3.07 31.71
29.61 3.02 38.37
30.36 2.94 22.90
31.47 2.84 5.28
32.58 2.75 4.08
33.08 2.71 16.59
34.96 2.57 3.05
36.61 2.45 10.14
37.96 2.37 5.46
39.15 2.30 2.87
实施例6 晶型CS2的制备方法
将8.5mg的Vadadustat固体置于1.5mL的玻璃小瓶中，加入0.075mL的丙酮，固体溶解得到澄清溶液。磁力搅拌下，将1.5mL的水缓慢滴入澄清溶液中。室温下继续搅拌24h，过滤干燥得到固体。
经检测，本实施例得到的固体为晶型CS2。本实施例所得固体的X射线粉末衍射数据如表6所示。
表6
衍射角2θ d值 相对强度％
3.62 24.41 10.56
10.94 8.09 61.20
12.60 7.02 5.16
13.40 6.61 17.01
14.09 6.28 7.31
14.62 6.06 8.05
15.06 5.88 18.83
16.11 5.50 12.39
18.32 4.84 100.00
20.08 4.42 11.34
21.52 4.13 9.31
22.02 4.04 77.03
24.63 3.61 11.58
25.48 3.50 8.60
25.80 3.45 18.90
27.01 3.30 3.42
27.90 3.20 3.13
28.47 3.13 3.45
29.14 3.06 6.91
29.63 3.02 20.38
30.37 2.94 6.25
31.50 2.84 1.81
33.08 2.71 9.66
35.01 2.56 1.43
36.63 2.45 3.74
38.03 2.37 2.39
实施例7 晶型CS2的制备方法
将9.2mg的Vadadustat固体置于1.5mL的玻璃小瓶中，加入0.1mL的1,4-二氧六环，固体溶解得到澄清溶液。磁力搅拌下，将1.5mL的水缓慢滴入澄清溶液中。室温下继续搅拌24h，过滤干燥得到固体。
经检测，本实施例得到的固体为晶型CS2。本实施例所得固体的X射线粉末衍射数据如表7所示。
表7
衍射角2θ d值 相对强度％
3.65 24.22 13.30
10.94 8.09 58.16
12.61 7.02 3.77
13.38 6.62 16.57
14.11 6.28 6.10
14.66 6.04 5.85
15.05 5.89 26.10
16.12 5.50 11.93
17.33 5.12 4.33
18.32 4.84 100.00
20.07 4.43 16.14
21.54 4.13 9.59
22.04 4.03 71.63
24.53 3.63 16.59
25.44 3.50 11.92
25.76 3.46 23.96
27.88 3.20 4.79
28.48 3.13 4.57
29.10 3.07 9.35
29.63 3.01 22.22
30.35 2.95 9.30
31.32 2.86 4.35
33.10 2.71 11.03
34.91 2.57 1.94
36.63 2.45 5.98
37.98 2.37 3.20
实施例8 晶型CS2的制备方法
将8.2mg的Vadadustat固体置于1.5mL的玻璃小瓶中，加入0.05mL的二甲亚砜，固体溶解得到澄清溶液。磁力搅拌下，将1.5mL的水缓慢滴入澄清溶液中。室温下继续搅拌24h，过滤干燥得到固体。
经检测，本实施例得到的固体为晶型CS2。本实施例所得固体的X射线粉末衍射数据如表8所示。
表8
衍射角2θ d值 相对强度％
3.56 24.78 14.42
10.93 8.09 75.55
12.64 7.00 7.88
13.41 6.60 25.33
14.12 6.27 13.27
14.68 6.04 8.56
15.13 5.86 25.16
16.15 5.49 16.80
17.36 5.11 5.49
18.32 4.84 100.00
20.05 4.43 22.61
22.02 4.04 73.20
24.49 3.63 34.96
25.80 3.45 35.47
26.98 3.30 6.55
28.50 3.13 9.04
29.14 3.06 17.18
29.65 3.01 30.41
30.36 2.94 12.75
33.09 2.71 12.79
34.83 2.58 2.66
36.61 2.45 10.66
37.95 2.37 4.69
实施例9 晶型CS2的稳定性
稳定性对比实验：称取约4mg的晶型CS2和约4mg专利WO2015073779晶型A于1.5mL的玻璃小瓶中，加入1.0mL水，测试起始样品的晶型，在室温以500r/min的速率搅拌约40天，再次进行XRPD测试，XRPD对比图如图13所示。结果表明，混悬竞争实验进行到40天时，专利WO2015073779晶型A已基本转变为晶型CS2，说明在水中晶型CS2比专利WO2015073779晶型A更稳定。
加速实验：将本发明制备得到的晶型CS2在25℃/60％相对湿度(RH)、40℃/75％相对湿度(RH)、60℃/75％相对湿度(RH)的条件下放置1个月；分别测定放置前后XRPD，实验结果见表9，晶型CS2放置在上述条件下1个月前后的XRPD对比图如图11所示。结果表明，晶型CS2在25℃/60％RH，40℃/75％RH，60℃/75％RH条件下放置1个月晶型保持不变。
表9
Figure PCTCN2017115909-appb-000006
机械稳定性实验：将晶型晶型CS2置于研钵中，手动研磨5分钟。测试研 磨后晶型CS2的XRPD图样，研磨前后XRPD图如图12所示。
实施例10 晶型CS2的引湿性
称取10mg本发明晶型CS2，采用动态水分吸附仪(DVS)测试其引湿性，结果表明从40％相对湿度到80％相对湿度区间，晶型CS2增重0.11％，其引湿性较低。
实施例11 晶型CS2的压片稳定性
将晶型CS2采用ENERPAC型手动压片机进行压片。压片时，选择直径为6mm的圆形平冲(保证片剂的各向同性)，分别采用3KN、7KN、14KN的压力压制成圆形片剂，压片前后在Panalytical Empyrean X射线粉末衍射仪上采集XRPD，如图15所示。结果表明，与压片前相比，压片后晶型没有发生变化，晶型CS2具有较好的压片稳定性。
实施例12 晶型CS2的片剂制剂
按表10的片剂处方用量，将晶型CS2与辅料混合均匀，采用ENERPAC型手动压片机进行压片。压片时，选择直径为6mm的圆形平冲，压力为10KN，压制成圆形片剂。
将片剂用HDPE瓶封装，放置于30℃/65％相对湿度的条件下3个月，考察晶型CS2的制剂稳定性。并于3个月末进行取样检测晶型的变化，结果表明晶型CS2在30℃/65％相对湿度条件下至少可以稳定3个月。
表10
片剂成分 用量mg/片
API(CS2) 32.00
微晶纤维素(PH105250) 56.86
羧甲基淀粉钠(DST) 7.00
十二烷基硫酸钠 1.00
聚乙烯吡啶酮(聚维酮K29/32) 2.69
二氧化硅(胶体)(AEROSIL 200Pharma) 0.25
硬脂酸镁(5712) 0.20
合计 100.00
实施例13 晶型CS8的制备方法
将8.3mg的Vadadustat固体置于1.5mL的玻璃小瓶中，加入0.65mL的丙酮和水的混合溶剂(丙酮与水的体积比为6:7)，在50℃下固体溶解得到澄清溶液。将澄清溶液转移至5℃环境，搅拌过夜，有固体析出。
经检测，本实施例得到的固体为晶型CS8。本实施例所得固体的X射线粉末衍射数据如表11所示，其XRPD图如图8所示。
晶型CS8的DSC图如图9所示。
表11
衍射角2θ d值 相对强度％
10.58 8.36 1.13
11.87 7.45 1.95
12.31 7.19 2.02
13.48 6.57 4.77
13.92 6.36 7.95
14.61 6.06 2.87
15.81 5.60 6.28
16.52 5.37 5.64
17.22 5.15 4.83
18.63 4.76 1.41
19.48 4.56 3.31
20.48 4.34 2.20
21.23 4.19 9.24
21.89 4.06 5.59
22.64 3.93 13.38
23.34 3.81 5.54
23.55 3.78 3.72
25.11 3.55 3.70
25.54 3.49 4.93
26.81 3.33 100.00
27.52 3.24 6.82
28.68 3.11 4.96
35.15 2.55 1.02
38.66 2.33 1.03
39.33 2.29 0.74
实施例14 晶型CS8的动态溶解度
分别称取一定量的本发明晶型CS8和专利WO2015073779晶型A置于小瓶中，分别用SGF(模拟胃液)和水进行溶解。在旋转器上以25r/min的速率旋转，并分别于1小时、4小时和24小时取样，在使用0.45μm PTFE过滤器离心分离后，收集滤液进行HPLC分析，结果如表12、13所示。
表12
Figure PCTCN2017115909-appb-000007
表13
Figure PCTCN2017115909-appb-000008
结果表明，在SGF和水中放置1小时，4小时和24个小时后，本发明的 晶型CS8与专利WO2015073779晶型A相比，其溶解度均高于专利WO2015073779晶型A的溶解度。
实施例15 晶型CS8的稳定性
将本发明制备得到的晶型CS8在5℃/60％相对湿度(RH)、40℃/75％相对湿度(RH)、60℃/75％相对湿度(RH)的条件下放置20天，分别测定放置前后XRPD，实验结果见表14。
表14
Figure PCTCN2017115909-appb-000009
结果表明，晶型CS8在25℃/60％RH，40℃/75％RH，60℃/75％RH条件下放置20天晶型保持不变。本发明所提供晶型CS8具有良好的稳定性。
实施例16 晶型CS8的引湿性
称取10mg本发明晶型CS8，采用动态水分吸附仪(DVS)测试其引湿性，DVS图如图14所示。结果表明，在80％相对湿度时，晶型CS8增重0.06％，属于无或几乎无引湿性。
《中国药典》通则9103对引湿性特征描述与引湿性增重的界定：
潮解：吸收足量水分形成液体。
极具引湿性：引湿增重不小于15％。
有引湿性：引湿增重小于15％但不小于2％。
略有引湿性：引湿增重小于2％但不小于0.2％。
无或几乎无引湿性：引湿增重小于0.2％。
上述实施例只为说明本发明的技术构思及特点，其目的在于让熟悉此项技术的人士能够了解本发明的内容并据以实施，并不能以此限制本发明的保护范围。凡根据本发明精神实质所作的等效变化或修饰，都应涵盖在本发明的保护范围之内。

Claims (16)

  1. 一种{[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的晶型CS1，其特征在于，其X射线粉末衍射图在2θ值为13.9°±0.2°、15.3°±0.2°、15.6°±0.2°、26.8°±0.2°处具有特征峰。
  2. 根据权利要求1所述的晶型CS1，其特征还在于，其X射线粉末衍射图在2θ值为17.0°±0.2°、19.1°±0.2°、23.5°±0.2°、25.6°±0.2°中的一处或多处具有特征峰。
  3. 一种权利要求1所述晶型CS1的制备方法，其特征在于，晶型CS1可以通过以下两种方法的任一种得到:
    1)将{[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸固体溶于醚类溶剂中，于室温下挥发得到固体；
    2)将{[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸固体溶于四氢呋喃溶剂中，向溶液中缓慢滴加水或者将溶液滴加到水中，于室温下搅拌一段时间，过滤干燥得到固体。
  4. 根据权利要求3所述CS1的制备方法，其特征在于，所述醚类为甲基叔丁基醚；所述搅拌时间为1-48h。
  5. 一种{[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的晶型CS2，其特征在于，其X射线粉末衍射图在2θ值为14.1°±0.2°、15.0°±0.2°、18.3°±0.2°处具有特征峰。
  6. 根据权利要求5所述的晶型CS2，其特征还在于，其X射线粉末衍射图在2θ值为12.6°±0.2°、13.4°±0.2°、22.0°±0.2°中的一处或两处或三处具有特征峰。
  7. 根据权利要求5所述的晶型CS2，其特征还在于，其X射线粉末衍射图在2θ值为10.9°±0.2°、16.1°±0.2°、20.1°±0.2°中的一处或两处或三处具有特征峰。
  8. 一种权利要求5所述晶型CS2的制备方法，其特征在于，晶型CS2可以通过将{[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸溶解到酮类、1,4-二氧六环或二甲亚砜溶剂中，向溶液中缓慢添加水或者将溶液滴加到水中，于室温下搅拌一段时间，过滤干燥得到固体。
  9. 根据权利要求8所述CS2的制备方法，其特征在于，所述酮类为丙酮；所述搅拌时间为1-48h。
  10. 一种{[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的晶型CS8，其特征 在于，其X射线粉末衍射图在2θ值为21.2°±0.2°、22.6°±0.2°、26.8°±0.2°处具有特征峰。
  11. 根据权利要求10所述的晶型CS8，其特征还在于，其X射线粉末衍射图在2θ值为13.5°±0.2°、13.9°±0.2°、15.8°±0.2°、21.9°±0.2°、28.7°±0.2°中的一处或多处具有特征峰。
  12. 一种权利要求10所述晶型CS8的制备方法，其特征在于，晶型CS8可以通过将{[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸固体溶解于酮类和水的混合溶剂中，将所得澄清溶液置于5℃，搅拌一段时间，过滤干燥得到固体。
  13. 根据权利要求12所述CS8的制备方法，其特征在于，所述溶解温度为40-56℃；所述酮类溶剂为丙酮；所述丙酮和水的混合体积比为1:3-2:1；所述搅拌时间为8-48h。
  14. 一种药物组合物，所述药物组合物包含有效治疗量的权利要求1所述的晶型CS1，或权利要求5所述的晶型CS2，或权利要求10所述的晶型CS8及其混合物药学上可接受的载体、稀释剂或赋形剂。
  15. 权利要求1所述的晶型CS1，或权利要求5所述的晶型CS2，或权利要求10所述的晶型CS8，或它们的任意混合在生产用于制备治疗贫血症药物中的用途。
  16. 权利要求1所述的晶型CS1，或权利要求5所述的晶型CS2，或权利要求10所述的晶型CS8，或它们的任意混合在生产用于制备治疗慢性肾病贫血药物中的用途。
PCT/CN2017/115909 2016-12-13 2017-12-13 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法 WO2018108101A1 (zh)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US16/468,848 US10703724B2 (en) 2016-12-13 2017-12-13 Crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation thereof
EP17881314.3A EP3549932B1 (en) 2016-12-13 2017-12-13 Novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid and processes for preparation thereof
KR1020197020266A KR20190093651A (ko) 2016-12-13 2017-12-13 ((5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐)아미노)아세트산의 신규한 결정질 형태 및 이의 제조 방법
CA3046377A CA3046377C (en) 2016-12-13 2017-12-13 Novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid and processes for preparation thereof
AU2017376517A AU2017376517B2 (en) 2016-12-13 2017-12-13 Novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation thereof
EP20190094.1A EP3763703A3 (en) 2016-12-13 2017-12-13 Novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid and processes for preparation thereof
CN201780075695.1A CN110088088B (zh) 2016-12-13 2017-12-13 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法
ES17881314T ES2831863T3 (es) 2016-12-13 2017-12-13 Nuevas formas cristalinas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético y procesos de preparación de las mismas
MX2019006883A MX2019006883A (es) 2016-12-13 2017-12-13 Formas cristalinas novedosas de ácido {[5-(3-clorofenil)-3-idroxip iridina-2-carbonilo] amino} acético y procedimientos para la preparación del mismo.
JP2019531739A JP2020500925A (ja) 2016-12-13 2017-12-13 ｛［５−（３−クロロフェニル）−３−ヒドロキシピリジン−２−カルボニル］アミノ｝酢酸の新規結晶形及びその製造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201611148362 2016-12-13
CN201611148362.0 2016-12-13

Publications (1)

Publication Number Publication Date
WO2018108101A1 true WO2018108101A1 (zh) 2018-06-21

Family

ID=62558034

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/115909 WO2018108101A1 (zh) 2016-12-13 2017-12-13 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法

Country Status (10)

Country Link
US (1) US10703724B2 (zh)
EP (2) EP3549932B1 (zh)
JP (1) JP2020500925A (zh)
KR (1) KR20190093651A (zh)
CN (1) CN110088088B (zh)
AU (1) AU2017376517B2 (zh)
CA (1) CA3046377C (zh)
ES (1) ES2831863T3 (zh)
MX (1) MX2019006883A (zh)
WO (1) WO2018108101A1 (zh)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020075199A1 (en) * 2018-10-12 2020-04-16 Mylan Laboratories Limited Polymorphic forms of vadadustat
WO2020108941A1 (en) 2018-11-28 2020-06-04 Sandoz Ag Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor
WO2021120874A1 (zh) * 2019-12-17 2021-06-24 浙江大学 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用
IT202000014116A1 (it) 2020-06-12 2021-12-12 Olon Spa Nuovo composto cristallino di vadadustat
WO2022048613A1 (zh) * 2020-09-04 2022-03-10 广东东阳光药业有限公司 一种低氧诱导因子脯氨酰羟化酶抑制剂的晶型及其制备方法
US11970450B2 (en) 2018-11-28 2024-04-30 Sandoz Ag Multi-component crystals of an orally available HIF prolyl hydroxylase inhibitor

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2886896C (en) 2012-10-12 2020-03-10 Blue Sky Mines Ltd. Methods of and systems for treating incinerated waste
PE20160945A1 (es) 2013-11-15 2016-09-26 Akebia Therapeutics Inc Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acetico, composiciones, y usos de las mismas
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
GB202011431D0 (en) 2020-07-23 2020-09-09 Johnson Matthey Plc Polymorphs of vadadustat and methods for preparing the polymorphs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506149A (zh) * 2006-06-26 2009-08-12 宝洁公司 脯氨酰羟化酶抑制剂及使用方法
WO2012170377A1 (en) * 2011-06-06 2012-12-13 Akebia Therapeutics Inc. Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
WO2015073779A1 (en) 2013-11-15 2015-05-21 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2016153996A1 (en) * 2015-03-20 2016-09-29 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105837502A (zh) * 2016-04-05 2016-08-10 湖南欧亚生物有限公司 一种Vadadustat的合成方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506149A (zh) * 2006-06-26 2009-08-12 宝洁公司 脯氨酰羟化酶抑制剂及使用方法
WO2012170377A1 (en) * 2011-06-06 2012-12-13 Akebia Therapeutics Inc. Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
WO2015073779A1 (en) 2013-11-15 2015-05-21 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
CN105916502A (zh) * 2013-11-15 2016-08-31 阿克比治疗有限公司 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的固体形式，其组合物和用途
WO2016153996A1 (en) * 2015-03-20 2016-09-29 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
K. KNAPMAN, MODERN DRUG DISCOVERY, vol. 3, 2000, pages 53 - 54,57
See also references of EP3549932A4

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020075199A1 (en) * 2018-10-12 2020-04-16 Mylan Laboratories Limited Polymorphic forms of vadadustat
WO2020108941A1 (en) 2018-11-28 2020-06-04 Sandoz Ag Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor
US11970450B2 (en) 2018-11-28 2024-04-30 Sandoz Ag Multi-component crystals of an orally available HIF prolyl hydroxylase inhibitor
WO2021120874A1 (zh) * 2019-12-17 2021-06-24 浙江大学 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用
IT202000014116A1 (it) 2020-06-12 2021-12-12 Olon Spa Nuovo composto cristallino di vadadustat
WO2021250624A1 (en) * 2020-06-12 2021-12-16 Olon S.P.A. Novel crystalline compound of vadadustat
WO2022048613A1 (zh) * 2020-09-04 2022-03-10 广东东阳光药业有限公司 一种低氧诱导因子脯氨酰羟化酶抑制剂的晶型及其制备方法

Also Published As

Publication number Publication date
EP3549932B1 (en) 2020-09-30
CN110088088A (zh) 2019-08-02
CA3046377C (en) 2021-03-30
ES2831863T3 (es) 2021-06-09
EP3763703A3 (en) 2021-03-03
AU2017376517A1 (en) 2019-07-25
AU2017376517B2 (en) 2021-03-25
KR20190093651A (ko) 2019-08-09
MX2019006883A (es) 2019-10-21
JP2020500925A (ja) 2020-01-16
US20200095203A1 (en) 2020-03-26
US10703724B2 (en) 2020-07-07
EP3549932A4 (en) 2020-01-01
EP3549932A1 (en) 2019-10-09
CN110088088B (zh) 2022-03-29
CA3046377A1 (en) 2018-06-21
EP3763703A2 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
WO2018108101A1 (zh) {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法
WO2018184185A1 (zh) 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
WO2018036558A1 (zh) 一种雄激素受体拮抗剂药物的晶型及其制备方法和用途
WO2014082354A1 (zh) 西达本胺的晶型及其制备方法与应用
WO2019062854A1 (zh) 瑞博西林的共晶和瑞博西林单琥珀酸盐的共晶、其制备方法、组合物和用途
WO2019019959A1 (zh) 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途
JP2019516804A (ja) ナトリウム−グルコース共輸送体阻害薬の新規な結晶形及びその製造方法並びに用途
WO2018103726A1 (zh) 一种溴结构域蛋白抑制剂药物的晶型及其制备方法和用途
WO2016155670A1 (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
WO2019042219A1 (zh) 奥扎莫德盐酸盐的晶型及其制备方法
WO2020063939A1 (zh) 一种Upadacitinib的晶型及其制备方法和用途
WO2015176591A1 (zh) 贝曲西班盐及其制备方法和用途
CA3216258A1 (en) Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof
WO2018133705A1 (zh) Gft-505的晶型及其制备方法和用途
WO2019205812A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
WO2020057622A1 (zh) 卡博替尼苹果酸盐晶型及其制备方法和用途
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
WO2022258060A1 (zh) 一种lanifibranor的晶型及其制备方法
WO2019210511A1 (zh) 一种s1p1受体激动剂的加成盐及其晶型和药物组合物
WO2021000687A1 (zh) Pac-1晶型的制备方法
WO2018157741A1 (zh) Sb-939的盐的晶型及其制备方法和用途
WO2019105359A1 (zh) Acalabrutinib的晶型及其制备方法和用途
WO2020151672A1 (zh) 一种达格列净晶型及其制备方法和用途
WO2022144042A1 (zh) Tas-116的晶型及其制备方法、药物组合物和用途
US9981912B2 (en) Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17881314

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3046377

Country of ref document: CA

Ref document number: 2019531739

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20197020266

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017881314

Country of ref document: EP

Effective date: 20190702

ENP Entry into the national phase

Ref document number: 2017376517

Country of ref document: AU

Date of ref document: 20171213

Kind code of ref document: A